BNB PLUS CORP.
Close on Oct 19, 2026
- Market cap
- $878.33K
- P/E (TTM)
- –
- Dividend yield
- –
About Bnb Plus
Finance Services, SIC 6199
BNB Plus Corp. operates as a digital asset treasury company focused on accumulating and managing BNB, the native cryptocurrency of the Binance blockchain ecosystem, to generate yield through staking, decentralized finance opportunities, and liquidity provision. In addition, the company develops and commercializes proprietary cell-free nucleic acid manufacturing technologies through its subsidiary, LineaRx, Inc. These solutions include synthetic DNA and engineered RNA polymerase platforms, specifically LineaDNA, LineaRNAP, and LineaIVT, which serve biopharmaceutical and diagnostic markets for the production of advanced biotherapeutics like mRNA treatments, gene therapies, and diagnostic tools.
The company maintains corporate headquarters and dedicated research and manufacturing laboratories at the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York. Its corporate structure includes operating and asset-holding subsidiaries formed in Delaware and the British Virgin Islands, alongside digital assets held with institutional custodians based in the United States.
Summary of the business section of Bnb Plus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BNB PLUS CORP.
- Founded
- 1983
- Headquarters
- Stony Brook, NY
- Address
- 25 Health Sciences Drive
- Phone
- (631) 240-8800
- Website
- www.bnb.plus
- Employees
- 26, Sep 30, 2025
- Industry
- Finance Services
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- CBIZ CPAs P.C., Melville, NY
Stock & identifiers
- Ticker
- BNBX
- Exchange
- OTC
- Shares outstanding
- 6M, Aug 12, 2026
- Public float
- $10.50M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Jun 2, 2025; 1-for-50 reverse, Mar 14, 2025; 1-for-50 reverse, Mar 13, 2025; 1-for-20 reverse, Apr 25, 2024; 1-for-20 reverse, Apr 25, 2024; 1-for-40 reverse, Nov 1, 2019; 1-for-40 reverse, Oct 31, 2019; 1-for-60 reverse, Dec 15, 2014; 1-for-60 reverse, Oct 29, 2014
- SEC CIK
- 744452
- CUSIP
- 03815U607
- ISIN
- US03815U6073
- LEI
- 549300PCOT1RLQ23DL21
- EIN
- 59-2262718
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Beth Jantzen | Chief Financial Officer | 18,694 |
| Clay Shorrock | Chief Executive Officer | 18,695 |
| Lok Lee | Director | – |
| Todd Larsen | Director | – |
| Richard Lee Shorten Jr. | Director | – |
| Yacov A. Shamash | Director | 22,512 |
| Robert B. Catell | Director | 22,512 |
| Judith Murrah | Director | 18,694 |
| Joseph D. Ceccoli | Director | 22,512 |
| Joshua Kruger | Director | 75,302 |
| James Haft | Director | 22,590 |
| Elizabeth M. Schmalz | Director | 22,512 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Dr.Hayward | $387.62K | $387.62K | $297.35K | $107 | – |
| FY2023 Dr.Hayward | $468.00K | $468.00K | $514.92K | $107 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had a total of 26 employees, consisting of 3 in executive management, 5 in research and development, 6 in quality and compliance, 3 in finance, accounting and human resources, 3 in operations/production, 3 in sales and marketing, 1 in administration and support services, and 2 in information services.”
Corporate history
Events identified from SEC filings